Big Win for Secukinumab in Polymyalgia Rheumatic

(MedPage Today) -- LONDON--The interleukin (IL)-17A inhibitor secukinumab (Cosentyx) was clearly effective in treating polymyalgia rheumatica (PMR) in a phase III trial, researchers reported, even as they also published final data from a failed...